Concord Biotech Invests in Stellon Biotech Expansion

  Published 9 months ago

Concord Biotech invests $1,500 in Stellon Biotech, acquiring 75% via 15M shares at $0.0001 each to boost U.S. operations.

  • Stellon, a Delaware-based pre-revenue company formed in Dec 2024, supports Concord's product commercialization.
  • Investment funds marketing and expansion of pharmaceutical products in the U.S. market through Stellon.
  • Concord's ownership ensures strategic control over Stellon's growth and operational decisions.

You might like these

Thyrocare Q1 Profit Soars 50%

Telecom Profits Surge on ARPU Growth

India Launches New Rupee Overnight Rate SORR at 5.16%

CCI Annual Day: Sitharaman Champions Pro, Growth Regulation

RBI Study Probes Inflation Expectations

HDFC Bank Sells HDBFS Shares via IPO

August 2025 India WPI Inflation Highlights

News that matters the most ⚡